NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

MGNX

Macrogenics Inc

Jul 15 • 04:00PM ET

1.49

Dollar change -0.09
Percentage change -5.70	%

Healthcare • Biotechnology • USA • NASD

Peers: GILD MRNA ALNY EXEL ONC AGEN INCY ZLAB UBX DLTH

| Held by: VTI VXF IBB SCHA VTWO IWC VHT DFAS PRFZ VTWG

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.89	Insider Own	8.16%	Shs Outstand	63.09M	Perf Week	1.36%
Market Cap	94.00M	Forward P/E	-	EPS next Y	-1.73	Insider Trans	-0.01%	Shs Float	57.94M	Perf Month	-3.87%
Enterprise Value	-22.67M	PEG	-	EPS next Q	-0.42	Inst Own	80.14%	Short Float	7.81%	Perf Quarter	15.50%
Income	-55.81M	P/S	0.61	EPS this Y	-55.61%	Inst Trans	-5.03%	Short Ratio	3.66	Perf Half Y	-53.14%
Sales	154.05M	P/B	1.19	EPS next Y	-3.90%	ROA	-23.61%	Short Interest	4.52M	Perf YTD	-54.15%
Book/sh	1.25	P/C	0.61	EPS next 5Y	-25.45%	ROE	-60.25%	52W High	5.77 -74.18%	Perf Year	-67.96%
Cash/sh	2.44	P/FCF	-	EPS past 3/5Y	31.80% 19.47%	ROIC	-50.18%	52W Low	0.99 50.56%	Perf 3Y	-57.43%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	24.64% 18.50%	Gross Margin	85.04%	Volatility	6.96% 8.25%	Perf 5Y	-95.27%
Dividend TTM	-	EV/Sales	-0.15	EPS Y/Y TTM	-141.39%	Oper. Margin	-64.56%	ATR (14)	0.13	Perf 10Y	-95.96%
Dividend Ex-Date	-	Quick Ratio	3.11	Sales Y/Y TTM	255.31%	Profit Margin	-36.23%	RSI (14)	51.60	Recom	2.50
Dividend Gr. 3/5Y	- -	Current Ratio	3.28	EPS Q/Q	22.21%	SMA20	6.54%	Beta	1.63	Target Price	4.75
Payout	-	Debt/Eq	0.47	Sales Q/Q	44.90%	SMA50	0.28%	Rel Volume	0.33	Prev Close	1.58
Employees	341	LT Debt/Eq	0.41	Earnings	May 13 AMC	SMA200	-40.93%	Avg Volume	1.24M	Price	1.49
IPO	Oct 10, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.43% 37.52%	Trades		Volume	410,152	Change	-5.70%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-07-24	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Aug-01-24	Downgrade	BTIG Research	Buy → Neutral
Jul-31-24	Downgrade	Guggenheim	Buy → Neutral
Jul-31-24	Downgrade	B. Riley Securities	Buy → Neutral	$18 → $5
May-10-24	Downgrade	TD Cowen	Buy → Hold
May-10-24	Downgrade	Stifel	Buy → Hold	$29 → $7
May-10-24	Downgrade	BMO Capital Markets	Outperform → Market Perform	$24 → $8
Apr-26-24	Initiated	B. Riley Securities	Buy	$25
Apr-09-24	Upgrade	TD Cowen	Hold → Buy
Mar-04-24	Reiterated	BTIG Research	Buy	$12 → $24
Feb-14-24	Downgrade	H.C. Wainwright	Buy → Neutral	$12 → $14
Dec-20-23	Upgrade	Citigroup	Neutral → Buy	$7 → $13
Nov-07-23	Upgrade	Guggenheim	Neutral → Buy	$12
Mar-17-23	Downgrade	Guggenheim	Buy → Neutral
Nov-22-22	Downgrade	Cowen	Outperform → Market Perform
Nov-14-22	Upgrade	BMO Capital Markets	Market Perform → Outperform	$5.70 → $16
Jul-18-22	Downgrade	SMBC Nikko	Outperform → Neutral	$5
Jul-11-22	Downgrade	BMO Capital Markets	Outperform → Market Perform	$31 → $4
May-04-22	Downgrade	Guggenheim	Buy → Neutral
Feb-28-22	Upgrade	Citigroup	Neutral → Buy	$23 → $21

Show Previous Ratings

Jun-10-25 07:00AM	MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ Royalty Purchase Agreement (GlobeNewswire) +8.54%
Jun-03-25 04:30PM	MacroGenics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025 (GlobeNewswire) +8.63%
May-22-25 09:36AM	Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies (Zacks) +6.04%
May-21-25 11:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks) -5.10%
May-13-25 05:15PM	MacroGenics (MGNX) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
04:11PM	Loading…
04:11PM	MacroGenics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress and First Quarter 2025 Financial Results (GlobeNewswire)
May-12-25 09:46AM	What To Expect From Macrogenics Inc (MGNX) Q1 2025 Earnings (GuruFocus.com) +11.19%
07:15AM	Rockwell Medical (RMTI) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-08-25 07:40AM	Owens & Minor (OMI) Q1 Earnings Top Estimates (Zacks)
May-07-25 05:40PM	Biote Corp. (BTMD) Q1 Earnings and Revenues Surpass Estimates (Zacks)
May-06-25 04:30PM	MacroGenics Announces Date of First Quarter 2025 Financial Results (GlobeNewswire) -10.37%
May-01-25 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire)
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks) +6.78%
Apr-03-25 09:35AM	MacroGenics (MGNX) Loses -48.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks) -5.74%
02:19PM	Loading…
Mar-21-25 02:19PM	MacroGenics axes ADC drug following Phase II failure in prostate cancer (Clinical Trials Arena)
12:05PM	Macrogenics Inc (MGNX) Q4 2024: Everything You Need to Know Ahead of Earnings (GuruFocus.com)
09:29AM	Q4 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
03:05AM	Macrogenics Inc (MGNX) Q4 2024 Earnings Call Highlights: Revenue Surge Amid Rising Expenses (GuruFocus.com)
Mar-20-25 08:15PM	MacroGenics (MGNX) Q4 2024 Earnings Call Transcript (Motley Fool)
07:09PM	MacroGenics, Inc. (MGNX) Q4 2024 Earnings Call Transcript (SeekingAlpha)
07:00PM	MacroGenics (MGNX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates (Zacks)
06:50PM	MacroGenics (MGNX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:02PM	MacroGenics Provides Update on Corporate Progress and 2024 Financial Results (GlobeNewswire)
10:00AM	Here are the major earnings after the close today (SeekingAlpha)
Mar-19-25 05:35PM	MacroGenics FY 2024 Earnings Preview (SeekingAlpha) +6.34%
05:15PM	Capricor Therapeutics (CAPR) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-06-25 07:30AM	MacroGenics Announces Date of Fourth Quarter and Full Year 2024 Financial Results Conference Call (GlobeNewswire)
Feb-27-25 07:30AM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Dec-02-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) -6.78%
04:30PM	Loading…
Nov-06-24 04:30PM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire) +11.14% +6.44%
08:51AM	Q3 2024 MacroGenics Inc Earnings Call (Thomson Reuters StreetEvents)
02:25AM	Macrogenics Inc (MGNX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Developments (GuruFocus.com)
Nov-05-24 10:15PM	MacroGenics (MGNX) Q3 2024 Earnings Call Transcript (Motley Fool)
08:00PM	Here's What Key Metrics Tell Us About MacroGenics (MGNX) Q3 Earnings (Zacks)
07:30PM	MacroGenics (MGNX) Beats Q3 Earnings and Revenue Estimates (Zacks)
06:26PM	MacroGenics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-04-24 07:13AM	Earnings To Watch: Macrogenics Inc (MGNX) Reports Q3 2024 Result (GuruFocus.com)
Oct-30-24 07:30AM	MacroGenics Announces Leadership Transition (GlobeNewswire)
Oct-29-24 04:30PM	MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call (GlobeNewswire) -5.11%
Oct-23-24 08:41AM	TerSera acquires global rights to MacroGenics' MARGENZA for breast cancer treatment (Pharmaceutical Business Review)
Oct-22-24 07:30AM	MacroGenics Enters Into Agreement With TerSera Therapeutics for the Sale of MARGENZA (Business Wire)
Sep-24-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
Sep-23-24 11:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile) -6.71%
Sep-20-24 05:06AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-19-24 01:29PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Sep-17-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire)
Sep-15-24 03:00AM	MacroGenics Announces Updated Efficacy & Safety Data from TAMARACK Phase 2 Study of Vobra Duo in mCRPC Patients at ESMO Congress 2024 (GlobeNewswire)
Sep-13-24 08:34AM	Do Options Traders Know Something About MacroGenics (MGNX) Stock We Don't? (Zacks)
Sep-11-24 08:30AM	MacroGenics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - MGNX (PR Newswire)
Sep-08-24 07:10PM	MacroGenics Announces TAMARACK Phase 2 Data Presentation at ESMO Congress 2024 (GlobeNewswire)
Sep-04-24 03:29PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Sep-03-24 05:45AM	Investors in MacroGenics, Inc. Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights - MGNX (PR Newswire) -6.55%
Sep-02-24 02:05PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-30-24 09:43AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-29-24 01:09PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-27-24 10:48AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-26-24 03:40PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire)
Aug-22-24 03:16PM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial Hagens Berman (GlobeNewswire) -7.50%
01:17PM	MacroGenics, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire)
Aug-21-24 07:05AM	MacroGenics (MGNX) Accused of Misleading Investors Over Cancer Drug Trial - Hagens Berman (Newsfile)
Aug-19-24 04:37PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire) +9.91%
Aug-17-24 03:29PM	Kessler Topaz Meltzer & Check, LLP Encourages MacroGenics, Inc. Investors with Losses to Contact the Firm (GlobeNewswire)
Aug-16-24 05:45AM	MacroGenics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - MGNX (PR Newswire)
04:26AM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis - Hagens Berman (Newsfile)
Aug-15-24 02:19PM	MacroGenics (MGNX) Under Fire as Analyst Downgrade Deepens Crisis Hagens Berman (GlobeNewswire)
Aug-14-24 12:19PM	MacroGenics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before September 24, 2024 to Discuss Your Rights MGNX (GlobeNewswire) -5.38%
Aug-13-24 02:31PM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit - Hagens Berman (Newsfile) +5.37%
12:45AM	MGNX INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that MacroGenics, Inc. Investors with Substantial Losses Have Opportunity to Lead Case (GlobeNewswire)
Aug-12-24 10:20AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit Hagens Berman (GlobeNewswire)
Aug-08-24 11:31AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit Hagens Berman (GlobeNewswire)
Aug-07-24 08:53AM	MacroGenics (MGNX) Halts Prostate Cancer Trial After Fatal Adverse Events, Investor Suit - Hagens Berman (Newsfile) -7.14%
Aug-06-24 09:30PM	Compared to Estimates, MacroGenics (MGNX) Q2 Earnings: A Look at Key Metrics (Zacks)
05:30PM	MacroGenics (MGNX) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
04:33PM	MacroGenics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	MacroGenics Provides Update on Corporate Progress, Second Quarter 2024 Financial Results (GlobeNewswire)
Jul-30-24 04:10PM	MacroGenics Provides Vobramitamab Duocarmazine Update (GlobeNewswire) -28.38%
04:01PM	MacroGenics Announces Achievement of $100 Million in Milestones Related to Retifanlimab Collaboration with Incyte (GlobeNewswire)
Jul-24-24 01:29PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire)
Jul-16-24 03:57PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire) +11.49%
Jul-10-24 05:19PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire) +8.90%
Jul-03-24 05:34PM	MacroGenics (MGNX) Investigating Three of Five Patient Deaths in TAMARACK Study of Vobra Duo, Stock Flat After May 10, 2024 Crash Hagens Berman (GlobeNewswire)
Jun-20-24 01:28PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire)
Jun-13-24 12:29PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) -6.21%
Jun-11-24 07:45AM	MacroGenics to Participate in Upcoming Investor Conference (GlobeNewswire) +7.64%
May-29-24 12:44PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire)
May-25-24 12:00PM	3 Biotech Stocks That Could Be Millionaire-Makers: May Edition (InvestorPlace)
May-17-24 12:50PM	Early Detection Breakthrough: Biotech Companies Lead the Way in Pancreatic Cancer Treatment (PR Newswire) -14.75%
May-16-24 12:59PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) +8.70%
May-13-24 12:30PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) +32.33%
07:30AM	MacroGenics to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-10-24 06:01PM	MacroGenics (MGNX) Stock Crashes After Reporting Patient Deaths in TAMARACK Study Hagens Berman (GlobeNewswire) -77.44%
04:51PM	Macrogenics Stock Drops 77% After Study Deaths (The Wall Street Journal)
03:29PM	Macrogenics Inc (MGNX) Q1 2024 Earnings: Misses Revenue Estimates Amidst Ongoing Clinical ... (GuruFocus.com)
03:17PM	MacroGenics, Inc. (NASDAQ:MGNX) Q1 2024 Earnings Call Transcript (Insider Monkey)
02:01PM	Top Midday Decliners (MT Newswires)
08:35AM	Why Is Macrogenics (MGNX) Stock Down 69% Today? (InvestorPlace)
07:48AM	Top Premarket Decliners (MT Newswires)

MacroGenics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of antibody-based therapeutics for the treatment of cancer. Its product pipeline includes Margetuximab, Flotetuzumab, Retifanlimab, Enoblituzumab, Tebotelimab, MGC018, MGD019, IMGC936, and MGD014 for infectious diseases. The company was founded by Scott E. Koenig, Jeffrey V. Ravetch, LeRoy E. Hood, Ruedi Aebersold, and Alan Aderem on August 14, 2000 and is headquartered in Rockville, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Bonvini Ezio	Sr VP, Research & CSO	Feb 15 '25	Option Exercise	0.00	16,665	0	124,414	Feb 19 04:31 PM
Karrels James	SVP, CFO and Secretary	Feb 15 '25	Option Exercise	0.00	14,998	0	192,591	Feb 19 04:29 PM
Koenig Scott	President and CEO	Feb 15 '25	Option Exercise	0.00	42,329	0	777,415	Feb 19 04:28 PM
Peters Jeffrey Stuart	Senior VP and General Counsel	Feb 15 '25	Option Exercise	0.00	13,332	0	18,858	Feb 19 04:25 PM
Risser Eric Blasius	Chief Operating Officer	Feb 15 '25	Option Exercise	0.00	16,665	0	62,422	Feb 19 04:24 PM
Smith Beth Ann	VP, Controller & Treasurer	Feb 15 '25	Option Exercise	0.00	1,095	0	9,955	Feb 19 04:23 PM
Smith Beth Ann	VP, Controller & Treasurer	Feb 15 '25	Sale	2.56	423	1,083	9,532	Feb 19 04:23 PM
Spitznagel Thomas	Sr VP, Technical Ops	Feb 15 '25	Option Exercise	0.00	13,332	0	26,922	Feb 19 04:22 PM
Eck Stephen L.	Chief Medical Officer	Feb 15 '25	Option Exercise	0.00	16,665	0	34,319	Feb 19 04:20 PM
Eck Stephen L.	Chief Medical Officer	Feb 08 '25	Option Exercise	0.00	11,168	0	20,966	Feb 11 08:34 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

MGNX

Macrogenics Inc

Upgrade your FINVIZ experience